

Influenza Work Group—Introduction

Dr. Jamie Loehr (Work Group Chair)

Advisory Committee on Immunization Practices

April 15, 2025

Influenza Work Group

ACIP Members

- Jamie Loehr (Chair)
- Robert Schechter
- Albert Shaw
- Keipp Talbot

Ex Officio

- Timothy Brennan (FDA)
- Uzo Chukwuma (IHS)
- Walter Greenhalgh (HRSA)
- Michael Ison (NIH)
- Cynthia Nolletti (FDA)
- Jo Resnick (FDA)
- Chris Roberts (NIH)

Liaison Representatives and Consultants

- Robert Atmar
- Kevin Ault
- Ed Belongia
- Hank Bernstein
- Kris Bryant
- Sarah Coles
- Sandra Fryhofer
- Robert Hopkins
- Wendy Keitel
- Camille Kotton
- Krissy Moehling
- Zackary Moore
- Flor Munoz
- Caitlin Newhouse
- Jesse Papenburg
- William Schaffner
- Ken Schmader
- Tamara Sheffield
- Angela Sinilaite
- Peter Szilagyi
- Matthew Zahn

CDC Lead

- Lisa Grohskopf

CDC Participants

- Lenee Blanton
- Karen Broder
- Alicia Budd
- Kayla Calhoun
- Jessie Chung
- Jennifer DeCuir
- Sascha Ellington
- Tarayn Fairlie
- Jill Ferdinands
- Brendan Flannery
- Andrew Kroger
- Samantha Olson
- David Shay
- Tom Shimabukuro
- Naomi Tepper

Influenza Vaccine Composition for 2025-26

- On March 15, 2025, the U. S. Food and Drug Administration made recommendations for the composition of U.S.-licensed influenza vaccines for the 2025-26 influenza season.
- The 2025-26 vaccine composition includes an update to the influenza A(H3N2) component.
 - For egg-based vaccines:
 - › an A/Victoria/4897/2022 (H1N1)pdm09-like virus;
 - › an A/Croatia/10136RV/2023 (H3N2)-like virus; and
 - › a B/Austria/1359417/2021 (B/Victoria lineage)-like virus
 - For cell culture and recombinant vaccines:
 - › an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;
 - › an A/District of Columbia/27/2023 (H3N2)-like virus; and
 - › a B/Austria/1359417/2021 (B/Victoria lineage)-like virus

Influenza Vaccine Effectiveness (VE) Estimates

Issue:

- Influenza vaccine effectiveness varies and is assessed annually through several CDC platforms focusing on laboratory-confirmed influenza outpatient visits and hospitalizations in adult and pediatric populations.
- VE estimates are presented to the ACIP as they become available.
- Preliminary 2024-25 VE estimates are available from CDC platforms and from the California Department of Public Health.

Updates:

- ***Interim Estimates of 2024–25 Seasonal Influenza Vaccine Effectiveness***
 - *Dr. Aaron Frutos (CDC/NCIRD/ID)*
- ***Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza, California, October 2024—January 2025***
 - *Dr. Sophie Zhu (California Department of Public Health and CDC/PHIC) and Dr. Joshua Quint (California Department of Public Health)*

FluMist (LAIV3) Self-/Caregiver Administration

Issue:

- On September 20, 2024, FDA approved FluMist for self or caregiver administration.
- This program is expected to be available for the 2025-26 influenza season.

Updates:

- ***FluMist Self-/Caregiver Administration***
 - *Dr. Allyn Bandell, AstraZeneca*

Upcoming Votes

- Vote concerning updates to the 2025-26 ACIP influenza statement is expected at the June 2025 ACIP meeting.

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

